CM336 (BCMA/CD3 bispecific antibody)
IIT2024047
Phase 1 mab active
Quick answer
CM336 (BCMA/CD3 bispecific antibody) for Relapsed Refractory Multiple Myeloma (RRMM) is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Relapsed Refractory Multiple Myeloma (RRMM)
- Phase
- Phase 1
- Modality
- mab
- Status
- active